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Abstract
Lung cancer is the most common cause of cancer-related death in the world. The Dutch-Belgian Randomized Lung
Cancer Screening Trial (Dutch acronym: NELSON) was launched to investigate whether screening for lung cancer by
low-dose multidetector computed tomography (CT) in high-risk patients will lead to a decrease in lung cancer
mortality. The NELSON lung nodule management is based on nodule volumetry and volume doubling time assess-
ment. Evaluation of CT examinations in lung cancer screening can also include assessment of coronary calcification,
emphysema and airway wall thickness, biomarkers for major diseases that share risk factors with lung cancer. In this
review, a practical approach to the radiological evaluation of CT lung cancer screening examinations is described.
Keywords: Lung cancer; screening; multidetector computed tomography, population; pulmonary nodule; volume measurement.
Introduction
Lung cancer is the primary cancer in males and the
second in females, accounting for 18% of the total
number of deaths[1]. Despite advances in treatment, the
5-year survival rate is still only 15% or even less, as many
lung cancers are found at a relatively late stage[2]. Low-
dose computed tomography (CT) was proposed as a
promising screening method for early detection of lung
cancer.
The Dutch-Belgian Randomized Lung Cancer
Screening Trial (Dutch acronym: NELSON) was
launched in 2003. The hypothesis of the NELSON trial
is that lung cancer screening by low-dose spiral CT will
reduce 10-year lung cancer mortality by 25% in a high-
risk population. Details on participant recruitment and
the CT acquisition protocol are described elsewhere[3]. In
short, heavy (ex-)smokers between 50 and 75 years of age
underwent four rounds of low-dose CT screening in years
1, 2, 4, and 7. The NELSON lung nodule management is
based on volumetry and volume doubling time assess-
ment. Thin-slice thoracic CT images were acquired with
a slice thickness of 1mm, and a slice interval of 0.7mm,
allowing for volume measurements of pulmonary
nodules.
Evaluation of CT examinations in lung cancer screen-
ing can also include assessment of coronary calcification,
emphysema and the airway wall, markers for major dis-
eases that share risk factors with lung cancer[4]. In this
review, a practical approach to the radiological evalua-
tion of CT lung cancer screening examinations is




The assessment starts with evaluating whether a
newly detected nodule has purely benign characteristics
such as benign calcifications or is very small (515mm3)
(Fig. 1). If so, the nodule can be categorized as
benign, and needs no further evaluation. If the nodule
cannot be directly defined as benign, the nodule is further
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evaluated. Next, the density of the lung nodule is
assessed. A nodule can be solid, partial-solid, or non-
solid.
Size-based evaluation
Evaluation of nodule size is essential to determine nodule
growth. Evaluation methods for solid, partial-solid and
non-solid nodules are different.
Semi-automated volumetry measurements are used for
segmentable nodules (Fig. 2), e.g., solid nodules and the
solid part of partial-solid nodules. In the NELSON study,
approximately 98% of the nodules were solid, and thus
could be assessed using semi-automated software[5]. In
cases of inappropriate segmentation, the reader is
allowed to manually modify the segmentation for more
accurate segmentation, which then overrules the automat-
ically generated volumetry.
Manual measurement of diameters is performed in
cases of non-segmentable nodules (Fig. 3), e.g., non-
solid nodules and the non-solid part of partial-solid
nodules. Although partial-solid and non-solid nodules
constitute the minority of nodules that are detected, the
frequency of malignancy is higher[6,7].
Interscan variability in nodule size evaluation is inevi-
table. Based on validation studies with repeated low-dose
CT on the same day, in which the measurement error was
maximally 25%, nodule growth is defined as a change in
volume of at least 25% between two subsequent
examinations[8].
Additional nonsize-based evaluation
Beside nodule density, attachment type, shape, margin
and location should be taken into account when
evaluating a pulmonary nodule (Fig. 4). First, the attach-
ment of nodules (peri-fissural, vessel-attached, pleural-
based and intraparenchymal) is evaluated. Although
peri-fissural nodules may show growth at follow-up CT,
the malignancy potential of peri-fissural nodules is
low[9,10]. In addition, a previous study showed negligible
cancer risk in fast-growing vessel-attached and pleural-
based nodules 1 year after baseline[11]. Second, the
shape of nodules (spherical and non-spherical) is evalu-
ated. Non-spherical shape has been found to increase the
likelihood of malignancy, rather than spherical shape[12].
Third, the margin of nodules (smooth, lobulated, spicu-
lated or other) is assessed. In a subgroup of NELSON
with 469 solid intraparenchymal nodules, a lobulated or
spiculated margin increased the likelihood for
malignancy compared with a smooth margin[13].
Fourth, nodule location is defined by the pulmonary seg-
ment and according to distance to pleura: peripheral
nodules are defined as51/3 from total distance between
hilus-costal pleura, and central nodules are defined as
42/3 from this distance. In-between nodules are defined
as between 1/3 to 2/3 from total distance between hilus-
costal pleura.
Reading
A single CT lung cancer screening evaluation by an expe-
rienced reader seems sufficient. In the first three rounds
of the NELSON trial, images were evaluated twice. The
second reader was unaware of the conclusion of the first
reader. In cases of discrepancy, a third reader made the
final decision. However, based on the results from these
rounds, no statistically significant benefit was found for
consensus double reading for detection of lung cancer
Figure 1 A complete calcified nodule is considered as benign on a transverse thin-slice CT image in the soft tissue
setting (a). A very small (14mm3) nodule is not further evaluated (b, transverse thin-slice CT image in the lung setting).
The volume-rendered image of this small nodule is shown in (c).
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Figure 2 Screen capture of dedicated software to semi-automatically measure the volume of a solid nodule (LungCare,
Siemens, Forchheim, Germany). At the top left section, a thin maximum intensity projection is shown; in the yellow box,
the nodule of interest selected by the radiologist. The top right section shows a transverse thin-slice image. On the bottom
left, a coronal thin-slice image is shown, and a volume-rendered image of the selected nodule is shown bottom right.
Figure 3 Semi-automated volumetry for the solid part of a partial-solid nodule (a), and manual measurement of the
diameter for the non-solid part of this partial-solid nodule (b). Manual measurement of diameters is performed for a non-
solid nodule (c). (a) is a volume-rendered image; (b) and (c) are maximum intensity projection images.
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with the use of a nodule management strategy based on
semi-automated volumetry measurements[14]. Thereafter,
in the fourth round, only one reading was performed by
one of the two radiologists with at least 8 years of expe-
rience in thoracic imaging.
Images are interpreted on a workstation for
evaluation of pulmonary nodules and non-nodular dis-
eases (in the NELSON trial: Leonardo, Siemens,
Forchheim, Germany), both at lung window and mediast-
inal settings. When a pulmonary nodule is identified,
a dedicated software package (in the NELSON trial:
LungCare, Siemens, Forchheim, Germany) is used for
semi-automated volumetric measurement. In cases of
non-segmentable nodules, the reader should manually
measure the diameter of the lesion. In the LungCare
software package, previous and current images are
displayed simultaneously on the same screen for compar-
ison. Besides the evaluation of nodule size, nodule
characteristics (attachment type, margin, etc.) are then
also evaluated and reported.
Lung nodule decision management
Newly detected lung nodules are divided into four cate-
gories (NODCAT 1 to 4), based on nodule density and
size. In subsequent screening rounds, preexisting nodules
are defined as three categories (GROWCAT A to C),
based on nodule growth in terms of volume doubling
time (Table 1). For newly detected nodules, the test
result (negative, indeterminate and positive) is based on
the highest NODCAT. For preexisting nodules, the test
result is based on the highest GROWCAT. A negative
result indicates that no further workup is needed. The
participant is then invited to undergo the regular next-
round CT. An indeterminate result requires a follow-up
examination after 6 weeks (for incidence screening) to 3
months (for baseline screening). A positive result neces-
sitates referral to a pulmonologist for workup and diag-
nosis. The decision tree for baseline, second, third and
fourth rounds are shown in Figs. 5 and 6. An example of
a growing nodule that turned out to be lung cancer is
shown in Fig. 7.
Figure 4 Example images of four nodule attachment types: peri-fissural (a), vessel-attached (b), pleural-based (c) and
intraparenchymal (d). Example images of three margin types: smooth (e), lobulated (f) and spiculated (g). All images are
transverse thin-slice CT slices.
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Table 1 Nodule categorization based on size and density (new nodules) and growth rate (existing nodules) in the
NELSON trial
Category Definition
NODCAT 1 A benign nodule (with fat/benign calcifications) or other benign abnormalities
NODCAT 2 A nodule, smaller than NODCAT3, not belonging to NODCAT1
Solid Partial-solid Non-solid
NODCAT 3 50V 500mm3 Solid component: 50V 500mm3 dmean 8mm
Pleural-based: 5 dmin 10mm Non-solid component: dmean 8mm
NODCAT 4 V4500mm3 Solid component: V4500mm3 (non-existent category)
Pleural-based: dmin410mm
GROWCAT A VDT4600 days
GROWCAT B 400VDT 600 days
GROWCAT C VDT5400 days, or new solid component in non-solid lesion
V, volume; dmin, minimal diameter; dmean, mean diameter; VDT, volume doubling time
Figure 5 Decision tree of the baseline examination in the NELSON trial. PVC, percentage volume change.
Figure 6 Decision tree of the second, third and fourth round examination in the NELSON trial.
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Figure 7 New pulmonary nodule in the apicoposterior segment of the left superior lobe in the third round (a and b), non-
spherical, lobulated and solid, with volume of 54mm3 (NODCAT 3). In the fourth round, 3 years after the third round (c
and d), the volume had increased to 249mm3, and the volume doubling time was 284 days (GROWCAT C). Thus, this
was considered to be a positive case; the participant was referred to a pulmonologist. Lung cancer was confirmed.
(a) and (c) are thin maximum intensity projection images; (b) and (d) are volume-rendered images.
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NELSON management system
In the NELSON trial, evaluation results are exported into
the web-based NELSON management system (Fig. 8).
Nodule characteristics, volume and diameter are
recorded. Nodule volume is automatically compared
with the previous data to calculate the percentage
volume change and the volume doubling time in days.
The system then makes a suggestion for categorization of
pulmonary nodules.
Non-nodular diseases
Beside lung cancer originating from pulmonary
nodules, over 14% of participants in lung cancer
screening have other diseases, such as cardiovascular
disease and other pulmonary disease[15]. Aging and
smoking, the two major risk factors for lung cancer,
are also main contributors in the development and
progression of coronary calcification and emphy-
sema[16,17]. It is important to review the CT screening
examination for coronary artery calcification and
emphysema. These thoracic biomarkers can be evalu-
ated quantitatively.
A list of non-nodular findings that were initially
reported in the NELSON trial is given in Table 2. The
screening population of (ex-)smokers frequently shows
findings such as pleural plaques to a certain extent, with-
out having high clinical relevance. Thus, these were not
reported to the general practitioner, to prevent unneces-
sary costs and patient anxiety. Some severe diseases were
detected in the NELSON screening group that led to
clinical referral, e.g., abdominal aortic aneurysm and
renal cancer. However, the prevalence of these other
potentially significant findings in the NELSON trial is
only 1%, and the benefit for systematically searching
for these additional findings has been found to be
negligible[18].
Coronary calcification
Coronary calcification is a frequent finding in the
NELSON screening group, with a prevalence of over
70%[19]. Calcium scoring as part of low-dose CT lung
Figure 8 Screen capture of the web-based NELSON management system.
Table 2 Non-nodule radiological findings in lung cancer
CT screening
Clinical relevance too
low to report to GP
Clinically significant and
reported to GP
Aortic calcium Aortic aneurysm
Adrenal lesion 10HU Adrenal lesion410HU
Pleural calcifications Bone destruction
Pleural plaques Liver lesions
Pulmonary fibrosis Mass (thyroid, breast, abdominal, etc.)
Bronchiectasis Pleural fluid
Lymph node enlargement Pneumonia
Segmental or larger atelectasis
GP, general practitioner.
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cancer screening can be used as an independent predictor
of cardiovascular death and events[19,20]. For the analysis
of coronary calcification, the raw data should be recon-
structed into 3-mm thickness to improve interscan repro-
ducibility and make the settings more comparable with
the dedicated coronary calcium examination[21,22]. Then,
calcium scoring can be performed using the method
developed by Agatston[23].
Emphysema and airway wall
Emphysema is also a frequent finding in lung cancer
screening. The two primary causes of chronic obstructive
pulmonary disease (COPD) are emphysema and airway
remodelling[24]. In a meta-analysis, CT-measured emphy-
sema and airway wall thickness correlated with airflow
obstruction in COPD[25]. CT examinations obtained for
lung cancer screening can identify participants with
COPD, with a sensitivity of 63% and a specificity of
88%[26]. Among the parameters that can be used to quan-
tify emphysema, percentage of lung attenuation area
under 950HU, mean lung density and 15 percentile
point for lung density are the most commonly used.
Among the parameters to quantify airway wall thickness,
wall area percentage and wall thickness are the most
commonly used[25]. Dedicated software is needed to
obtain quantitative emphysema and airway wall
measures.
Conclusion
The NELSON trial is the first lung cancer screening trial
in which nodule management is based on semi-automated
volumetric measurements. High-resolution images
acquired in low-dose thin-slice CT result in accurate eval-
uation of nodule volume and volume doubling time.
Nodule volume and volume doubling time are used to
categorize a lung nodule according to risk of lung
cancer, and recommend adequate nodule management.
A 10-step practical approach to evaluate a CT lung
cancer screening examination is provided in Table 3.
Cardiovascular disease and COPD share risk factors
with lung cancer, such as aging and smoking. The
prevalence of these diseases in a lung cancer screening
population is high. Besides the evaluation of lung
nodules, low-dose thoracic CT can be used to evaluate
coronary calcification, emphysema and airway wall thick-
ness, and thereby estimate the risk of cardiovascular dis-
ease and COPD. An integrated evaluation of quantitative
biomarkers of these diseases can potentially enhance the
benefit of CT lung cancer screening.
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